A Red Blood Cell-Hitchhiking Dendrimer Nanovaccine Potentiates Antitumor Immunity via Lymphoid Organ Targeting
Biomacromolecules · 09.11.2026 · 27 (11) · 7614-7624
DOI: 10.1021/acs.biomac.6c01657 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomacromolecules, online erschienen am 20.10.2026. Verfasst von Yanying Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Advanced Fiber Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Bio…. Hauptthemen laut MEDLINE: Nanovaccines, Dendrimers, Erythrocytes, Cancer Vaccines. Die Arbeit nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC), Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Efficient antigen delivery to antigen-presenting cells remains a critical challenge in cancer nanovaccine development. In this study, we develop a dendrimer-based nanovaccine (DenV) for efficient tumor treatment and prevention via a red blood cell (RBC) hitchhiking strategy. Utilizing phenylboronic acid-grafted dendrimers, model antigen ovalbumin (OVA) and immune adjuvant CpG oligodeoxynucleotide (CpG ODN) can be efficiently co-loaded to get DenV with a relatively simple fabrication process. Upon further RBC anchoring, DenV@RBC demonstrates a distinct application feature from DenV with a desired delivery profile to lymphoid organs. In vivo antitumor results in a mouse subcutaneous melanoma model show that both DenV and DenV@RBC achieve excellent antitumor effects following systemic administration, where the therapeutic efficacy of DenV@RBC is slightly superior to that of DenV. Meanwhile, DenV and DenV@RBC allow excellent tumor-preventive effects, regardless of local or systematic administration routes. It is also found that DenV is more robust upon local injection, while DenV@RBC yields better tumor prevention performance when administered systemically via the bloodstream. Our study offers a dendrimer-based strategy with interaction to natural RBCs for the development of highly efficient nanovaccines and holds substantial application potential in the field of cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Advanced Fiber Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai2…
- Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai200336, China.
ORCID-Profile: Yue Gao, Xiangyang Shi, Mingwu Shen
Förderung
- National Natural Science Foundation of China (NSFC)
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Li, Y., Gao, Y., Xiao, X., Li, A., Xia, L., Ji, R., Zhang, J., Shi, X., & Shen, M. (2026). A Red Blood Cell-Hitchhiking Dendrimer Nanovaccine Potentiates Antitumor Immunity via Lymphoid Organ Targeting. Biomacromolecules, 27(11), 7614-7624. https://doi.org/10.1021/acs.biomac.6c01657
Vancouver
Li Y, Gao Y, Xiao X, Li A, Xia L, Ji R, et al. A Red Blood Cell-Hitchhiking Dendrimer Nanovaccine Potentiates Antitumor Immunity via Lymphoid Organ Targeting. Biomacromolecules. 2026;27(11):7614-7624. doi:10.1021/acs.biomac.6c01657
BibTeX
@article{Li2026,
author = {Li, Yanying and Gao, Yue and Xiao, Xianghao and Li, Aiyu and Xia, Lili and Ji, Ruiqi and Zhang, Jianjun and Shi, Xiangyang and Shen, Mingwu},
title = {A Red Blood Cell-Hitchhiking Dendrimer Nanovaccine Potentiates Antitumor Immunity via Lymphoid Organ Targeting},
journal = {Biomacromolecules},
year = {2026},
volume = {27},
number = {11},
pages = {7614--7624},
doi = {10.1021/acs.biomac.6c01657}
}
EUVIMED